ELDN

Eledon Pharmaceuticals, Inc. (ELDN) | Rumor.io

Eledon Pharmaceuticals

ELDN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,988

Bullish sentiment (50-day avg)83%

Price to earnings ratio2.71

Market capitalization214.5M

Earnings per share-0.9

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-45.6M

Social

What share of all stock conversation is about ELDN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 22

Eledon Pharmaceuticals, Inc. ($ELDN) announced updated long-term data from its Phase 2 BESTOW trial in kidney transplantation, showing improved kidney function.
The FDA granted Fast Track designation to tegoprubart, Eledon's investigational anti-CD40L antibody, for the prevention of rejection in kidney transplantation.
The stock price rose after the announcement, with a 24-month BESTOW data showing tegoprubart-treated patients had better eGFR and fewer rejections compared to tacrolimus.

Generated by AI

Sentiment

Of the messages about ELDN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +15.38	69.44% -24.03	82.9% -2.87
Bearish	—	0% -15.38	30.56% +24.03	17.1% +2.87

Bullish· Jun 22

Eledon Pharmaceuticals' Phase 2 study results showed statistically significant separation in kidney function compared to tacrolimus, a cheap but potentially less effective treatment.
The company's pipeline, particularly its kidney transplant therapy tegoprubart, has the potential to be standard of care if late-phase studies are successful.
Eledon's stock price is expected to continue to rise as awareness of the company and its products grows, with some analysts predicting a potential buyout from a big company in the future.

Bearish· Jun 22

The stock's price has missed expectations, with one investor stating it's "starting to stretch its legs" after a 30% decline.
The FDA's approval process is seen as ineffective, with one post calling it "useless".
The stock's short-term price action is unpredictable, with one investor joking that daytraders are "flipping pennies" and another predicting a sharp decline to $2.

Generated by AI

Topics

Of the messages about ELDN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	98.41%	66.94%
Analysts	—	0%	0%	10.6%
Technical Analysis	—	0%	1.59%	11.04%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	1.44%
Macro	—	0%	0%	9.97%

Dec 22

ELDN has been experiencing a 35% increase, with a possible slingshot formation and strong hands accumulating.
The stock has shown a bounce from $1.33 and $1.34, with increasing volume, and a close above $1.30-$1.35 is expected.
Technical indicators, such as the MACD, are lining up for a move upward, and a double bottom test at $1.38 is being considered.

Generated by AI

Community

Of the messages about ELDN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	90.7%	84.1%	41.09%
Newcomers	—	9.3%	15.9%	58.91%

Nov 19

Eledon Pharmaceuticals' preliminary results in a Phase I/II trial for Tegoprubart show promise in treating Type 1 Diabetes, with all six patients achieving full autonomy.
The trial, conducted at UChicago Medicine, used Tegoprubart as the core immunosuppressant to prevent rejection of transplanted islet cells in patients with Type 1 Diabetes.
Eledon Pharmaceuticals' stock price dipped by 4.22% to $1.48 on November 19, 2025, following the release of preliminary data from the trial.

Generated by AI

News

Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22

7d agoSeeking Alpha

Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ)

7d agoSeeking Alpha

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an app...

7d agomarkets.businessinsider.com

Eledon’s tegoprubart shows kidney function advantage in phase 2 trial

7d agoInvesting.com

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026. Details of the presentation are below: Oral Presentation Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evalua

21d agoYahoo Finance

Eledon submits IND for tegoprubart islet cell transplant study

27d agoInvesting.com

Also Discussed

Investors talking about ELDN also mention

#	Name	Attention
1	Corgi All Commodities 2x Daily ETFXCOM	0%0
2	EVOK - Evoke Pharma, Inc.	——
3	U.S. Gold Corp.USAU	0%0
4	Schmitt Industries Inc.SMIT	0%new
5	ADVM - Adverum Biotechnologies, Inc.	——
6	ALIM - Alimera Sciences, Inc.	——
7	MRNS - Marinus Pharmaceuticals, Inc.	——
8	BCEI - Civitas Resources, Inc.	——
9	NAVB - Navidea Biopharmaceuticals, Inc.	——
10	EAC - Edify Acquisition Corp.	——

Eledon Pharmaceuticals, Inc.

Healthcare
Biotechnology

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection. Eledon is currently advancing research programs in kidney transplantation, islet cell transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Its work centers on therapies intended to protect transplanted organs, reduce rejection risk, and address serious diseases with limited treatment options. Headquartered in Irvine, California, Eledon Pharmaceuticals operates as a focused drug development company within the broader biotechnology and immunology market.

Website

Location

19800 MacArthur Boulevard

Irvine, CA, 92612

United States

Social

What share of all stock conversation is about ELDN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 22

Eledon Pharmaceuticals, Inc. ($ELDN) announced updated long-term data from its Phase 2 BESTOW trial in kidney transplantation, showing improved kidney function.
The FDA granted Fast Track designation to tegoprubart, Eledon's investigational anti-CD40L antibody, for the prevention of rejection in kidney transplantation.
The stock price rose after the announcement, with a 24-month BESTOW data showing tegoprubart-treated patients had better eGFR and fewer rejections compared to tacrolimus.

Generated by AI

Sentiment

Of the messages about ELDN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% +15.38	69.44% -24.03	82.9% -2.87
Bearish	—	0% -15.38	30.56% +24.03	17.1% +2.87

Bullish· Jun 22

Eledon Pharmaceuticals' Phase 2 study results showed statistically significant separation in kidney function compared to tacrolimus, a cheap but potentially less effective treatment.
The company's pipeline, particularly its kidney transplant therapy tegoprubart, has the potential to be standard of care if late-phase studies are successful.
Eledon's stock price is expected to continue to rise as awareness of the company and its products grows, with some analysts predicting a potential buyout from a big company in the future.

Bearish· Jun 22

The stock's price has missed expectations, with one investor stating it's "starting to stretch its legs" after a 30% decline.
The FDA's approval process is seen as ineffective, with one post calling it "useless".
The stock's short-term price action is unpredictable, with one investor joking that daytraders are "flipping pennies" and another predicting a sharp decline to $2.

Generated by AI

Topics

Of the messages about ELDN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	98.41%	66.94%
Analysts	—	0%	0%	10.6%
Technical Analysis	—	0%	1.59%	11.04%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	1.44%
Macro	—	0%	0%	9.97%

Dec 22

ELDN has been experiencing a 35% increase, with a possible slingshot formation and strong hands accumulating.
The stock has shown a bounce from $1.33 and $1.34, with increasing volume, and a close above $1.30-$1.35 is expected.
Technical indicators, such as the MACD, are lining up for a move upward, and a double bottom test at $1.38 is being considered.

Generated by AI

Community

Of the messages about ELDN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	90.7%	84.1%	41.09%
Newcomers	—	9.3%	15.9%	58.91%

Nov 19

Eledon Pharmaceuticals' preliminary results in a Phase I/II trial for Tegoprubart show promise in treating Type 1 Diabetes, with all six patients achieving full autonomy.
The trial, conducted at UChicago Medicine, used Tegoprubart as the core immunosuppressant to prevent rejection of transplanted islet cells in patients with Type 1 Diabetes.
Eledon Pharmaceuticals' stock price dipped by 4.22% to $1.48 on November 19, 2025, following the release of preliminary data from the trial.

Generated by AI

Eledon Pharmaceuticals

Social

Sep 22

Bullish· Jun 22

Bearish· Jun 22

Dec 22

Nov 19

Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22

Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ)

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Eledon’s tegoprubart shows kidney function advantage in phase 2 trial

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Eledon submits IND for tegoprubart islet cell transplant study

Also Discussed

Eledon Pharmaceuticals, Inc.

Company Information

Location

Social

Sep 22

Bullish· Jun 22

Bearish· Jun 22

Dec 22

Nov 19

Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow (NASDAQ:ELDN) 2026-09-22

Eledon updates mid-stage trial data for lead drug (ELDN:NASDAQ)

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Eledon’s tegoprubart shows kidney function advantage in phase 2 trial

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

Eledon submits IND for tegoprubart islet cell transplant study

Also Discussed